Novo Nordisk today announced a new multi-month subscription program for Wegovy® (semaglutide) that provides eligible self-pay patients who enroll in the program through select telehealth providers a lower, predictable monthly price. The program is designed to reduce cost uncertainty and help people start and stay on FDA-approved obesity treatment.

This first and only subscription program for FDA-approved Wegovy® will be available beginning March 31, 2026, through Ro, WeightWatchers, LifeMD, with Hims & Hers, Sesame, and others to follow soon. Patients can save up to $600/year on the Wegovy® pill and up to $1,200/year on the Wegovy® injection with a 12-month subscription and should contact their telehealth providers directly for eligibility and enrollment details.